Page last updated: 2024-12-06

beclomethasone 17-monopropionate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Beclomethasone 17-monopropionate is a synthetic corticosteroid that is used as an inhaled medication to treat asthma and other respiratory conditions. It works by reducing inflammation in the airways. Beclomethasone 17-monopropionate is synthesized from the steroid hormone cortisone. It is a potent anti-inflammatory agent that has been shown to be effective in reducing the symptoms of asthma, allergic rhinitis, and other inflammatory conditions of the respiratory tract. Beclomethasone 17-monopropionate is studied because it is an important drug for the treatment of respiratory conditions. It is also being studied for its potential use in the treatment of other inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis.'

beclomethasone 17-monopropionate: ester of beclomethasone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62965
CHEMBL ID2115116
SCHEMBL ID102219
MeSH IDM0180921

Synonyms (28)

Synonym
beclomethasone 17-monopropionate
beclomethasone-17-monopropionate
CHEMBL2115116
9-chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate
pregna-1,4-diene-3,20-dione, 9-chloro-11,21-dihydroxy-16-methyl-17-(1-oxopropoxy)-, (11beta,16beta)-
einecs 226-888-1
unii-5bga9fd55h
5bga9fd55h ,
17-bmp
beclomethasone 17-propionate
9-chloro-11.beta.,21-dihydroxy-16.beta.-methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate
pregna-1,4-diene-3,20-dione, 9-chloro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-
beclomethasone dipropionate impurity h [ep impurity]
9-chloro-11b,17,21-trihydroxy-16b-methylpregna-1,4-diene-3,20-dione 17-monopropionate
SCHEMBL102219
1,4-pregnadien-9-alpha-chloro-16-beta-methyl-11-beta, 17,21-triol-3,20-dione17-propionate
DTXSID20203899 ,
AKOS030254508
beclometasone 17-propionate
(9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl propionate
DB14221
HY-136239
CS-0120927
Q27261789
(11beta,16beta)-9-chloro-11,21-dihydroxy-16-methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione
9-chloro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate
beclomethasone dipropionate impurity h (ep impurity)
dtxcid00126390

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The log-transformed pharmacokinetic data were compared for proportionality equivalence using a confidence-interval approach."( Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma.
Ekholm, BP; Harrison, LI; Kaiser, HB; Kurup, S; Larson, JS; Wagner, C, 2002
)
0.64
" Due to low levels, neither elimination half-life ( t(1/2)) nor the area under the plasma concentration-time curve (AUC) for 17-BMP could be calculated for the 100-microg BDP doses."( Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma.
Ekholm, BP; Harrison, LI; Kaiser, HB; Kurup, S; Larson, JS; Wagner, C, 2002
)
0.64
"We set out to evaluate lung deposition, systemic availability, and basic pharmacokinetic parameters of beclomethasone dipropionate (BDP) in children with chronic asthma."( Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children.
Agertoft, L; Harrison, LI; Laulund, LW; Pedersen, S, 2003
)
0.32
"Urinary pharmacokinetic methods have been identified to determine the relative lung and systemic bioavailability after an inhalation."( Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.
Chrystyn, H; Harding, LP; Said, AS, 2012
)
0.38
"The urinary pharmacokinetic methodology to determine the relative lung and systemic bioavailability post inhalation, using 30 min and cumulative 24 h post inhalation samples, applies to BDP."( Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.
Chrystyn, H; Harding, LP; Said, AS, 2012
)
0.38
"Open-label, prospective, randomized pharmacokinetic and pharmacodynamic study in healthy volunteers."( Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.
Alfaro, RM; Boyd, SD; Calderon, MM; Chairez, C; Hadigan, C; Kovacs, JA; McManus, M; Nieman, LK; Pau, AK; Penzak, SR, 2013
)
0.39
" Pharmacokinetic sampling for 17-BMP was performed on days 14 and 28, and pharmacokinetic parameter values were compared within patients and between groups."( Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.
Alfaro, RM; Boyd, SD; Calderon, MM; Chairez, C; Hadigan, C; Kovacs, JA; McManus, M; Nieman, LK; Pau, AK; Penzak, SR, 2013
)
0.39
" This pharmacokinetic study compared systemic exposure following beclomethasone dipropionate delivery through BAI versus MDI."( Pharmacokinetics of Beclomethasone Dipropionate Delivered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Subjects.
Gillespie, M; Small, CJ, 2018
)
0.48
" Mean elimination half-life was ∼4 hours."( Pharmacokinetics of Beclomethasone Dipropionate Delivered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Subjects.
Gillespie, M; Small, CJ, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" The mean absolute bioavailability (%F, 90% CI; nominal doses) of inhaled BDP was 2% (1-4%) and not reduced by coadministration of charcoal."( Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.
Daley-Yates, PT; Dallow, N; Pereira, A; Price, AC; Sisson, JR, 2001
)
0.31
"Unchanged BDP has negligible oral and intranasal bioavailability with limited absorption following inhaled dosing due to extensive (95%) presystemic conversion of BDP to B-17-MP in the lung."( Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.
Daley-Yates, PT; Dallow, N; Pereira, A; Price, AC; Sisson, JR, 2001
)
0.31
" The estimated bioavailability of BDP from the GI tract was 68%."( Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children.
Agertoft, L; Harrison, LI; Laulund, LW; Pedersen, S, 2003
)
0.32
" The aim of the study was to evaluate the pulmonary bioavailability for inhaled beclomethasone dipropionate (BDP) aerosols of different particle sizes."( Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size.
Esposito-Festen, JE; Lammers, JW; Tiddens, HA; Zanen, P, 2007
)
0.34
"Urinary pharmacokinetic methods have been identified to determine the relative lung and systemic bioavailability after an inhalation."( Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.
Chrystyn, H; Harding, LP; Said, AS, 2012
)
0.38
"The urinary pharmacokinetic methodology to determine the relative lung and systemic bioavailability post inhalation, using 30 min and cumulative 24 h post inhalation samples, applies to BDP."( Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.
Chrystyn, H; Harding, LP; Said, AS, 2012
)
0.38
" Using a previously developed urinary pharmacokinetic method, we have measured the relative lung and systemic bioavailability of beclometasone dipropionate (BDP) after inhalation from 2 hydrofluroalkane-beclometasone dipropionate (HFA-BDP) formulations when used with a spacer."( Bioavailability of Beclometasone From Two HFA-BDP Formulations With a Spacer.
AbuRuz, S; Chrystyn, H; Said, AS, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The contribution of the lung, nose and gut to the systemic exposure was assessed by repeating the inhaled, intranasal and oral dosing arms together with activated charcoal, to block oral absorption."( Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.
Daley-Yates, PT; Dallow, N; Pereira, A; Price, AC; Sisson, JR, 2001
)
0.31
" The mean percentage F of the active metabolite B-17-MP was 41% (31-54%), 44% (34-58%) and 62% (47-82%) for oral, intranasal and inhaled dosing without charcoal, respectively."( Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.
Daley-Yates, PT; Dallow, N; Pereira, A; Price, AC; Sisson, JR, 2001
)
0.31
"Unchanged BDP has negligible oral and intranasal bioavailability with limited absorption following inhaled dosing due to extensive (95%) presystemic conversion of BDP to B-17-MP in the lung."( Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.
Daley-Yates, PT; Dallow, N; Pereira, A; Price, AC; Sisson, JR, 2001
)
0.31
" Delivery of a potent glucocorticoid such as 17-BMP to the pulmonary artery after oral dosing of BDP may be useful in modulating pulmonary inflammation and preventing the development of non-infectious pulmonary complications after allogeneic HCT."( Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.
Chien, JW; Gooley, TA; McDonald, GB; Sakai, M; Schoch, HG, 2010
)
0.36
" Post oral dosing no BDP was detected in all urine samples and no 17-BMP or BOH was excreted in the first 30 min."( Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.
Chrystyn, H; Harding, LP; Said, AS, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID90104Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID91225Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay; Potent1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.00)18.7374
1990's4 (16.00)18.2507
2000's10 (40.00)29.6817
2010's9 (36.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.95 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (36.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]